{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:36:44Z","timestamp":1773113804827,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1999,4,1]],"date-time":"1999-04-01T00:00:00Z","timestamp":922924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":7572,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1999,4]]},"DOI":"10.1023\/a:1008364222793","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T09:41:38Z","timestamp":1040550098000},"page":"397-402","source":"Crossref","is-referenced-by-count":92,"title":["Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older"],"prefix":"10.1016","volume":"10","author":[{"given":"C.","family":"Vogel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Hochster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Adamkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"McGuirt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1023\/A:1008364222793_bb0005","first-page":"2493","article-title":"Cancer in the aged: An epidemiologic perspective on treatment issues","volume":"68","author":"Yancik","year":"1991","journal-title":"Cancer"},{"key":"10.1023\/A:1008364222793_bb0010","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/1097-0142(19890301)63:5<976::AID-CNCR2820630532>3.0.CO;2-A","article-title":"Breast cancer in aging women: A population-based study of contrasts in stage, surgery, and survival","volume":"63","author":"Yancik","year":"1989","journal-title":"Cancer"},{"key":"10.1023\/A:1008364222793_bb0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/(SICI)1097-0142(19960701)78:1<101::AID-CNCR15>3.0.CO;2-3","article-title":"Patterns of breast cancer care in the elderly","volume":"78","author":"Busch","year":"1996","journal-title":"Cancer"},{"key":"10.1023\/A:1008364222793_bb0020","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00000421-199510000-00006","article-title":"Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience","volume":"18","author":"Bruno","year":"1995","journal-title":"Am J Clin Oncol"},{"key":"10.1023\/A:1008364222793_bb0025","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1993.11.7.1245","article-title":"Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy","volume":"11","author":"Fumoleau","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008364222793_bb0030","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/oxfordjournals.annonc.a059019","article-title":"Phase II trial of weekly i.v. vinorelbine in first-line advanced breast cancer chemotherapy","volume":"5","author":"Garcia-Conde","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008364222793_bb0035","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.1994.12.2.336","article-title":"Vinorelbine as first-line chemotherapy for metastatic breast carcinoma","volume":"12","author":"Romero","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008364222793_bb0040","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/bjc.1994.435","article-title":"A phase II multicentre, UK study of vinorelbine in advanced breast cancer","volume":"70","author":"Twelves","year":"1994","journal-title":"Br J Cancer"},{"issue":"Suppl","key":"10.1023\/A:1008364222793_bb0045","first-page":"36","article-title":"The safety of i.v. Navelbine\u00ae in elderly patients with advanced breast cancer (ABC)","volume":"30","author":"Vogel","year":"1994","journal-title":"Breast Cancer Res Treat"},{"key":"10.1023\/A:1008364222793_bb0050","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.1995.13.11.2722","article-title":"Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer","volume":"13","author":"Weber","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008364222793_bb0055","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1200\/JCO.1995.13.10.2567","article-title":"Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer","volume":"13","author":"Jones","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008364222793_bb0060","first-page":"101","article-title":"A clinical trial of intravenous (i.v.) Navelbine (NVB) (vinorelbine tartrate) for first line treatment of women \u2265 60 years of age with advanced breast cancer (ABC)","volume":"15","author":"Vogel","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008364222793_bb0065","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0959-8049(96)00426-1","article-title":"Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer","volume":"33","author":"Sorio","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1023\/A:1008364222793_bb0070","first-page":"96","article-title":"Vinorelbine (VRL) as palliative treatment in elderly patients with metastatic breast cancer","volume":"46","author":"Buonadonna","year":"1997","journal-title":"Breast Cancer Res Treat"},{"key":"10.1023\/A:1008364222793_bb0075","first-page":"703","article-title":"A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women","volume":"83","author":"Gladieff","year":"1996","journal-title":"Bull Cancer"},{"key":"10.1023\/A:1008364222793_bb0080","first-page":"395","article-title":"Phase 11 study of tetrahydropyranyl Adriamycin (pirarubicin) in elderly patients with advanced breast cancer","volume":"15","author":"Chevallier","year":"1992","journal-title":"Am J Clin Oncol (CCT)"},{"key":"10.1023\/A:1008364222793_bb0085","first-page":"2297","article-title":"Mitoxantrone in elderly women with advanced breast cancer: A phase II study","volume":"15","author":"Repetto","year":"1995","journal-title":"Anticancer Res"},{"key":"10.1023\/A:1008364222793_bb0090","doi-asserted-by":"crossref","first-page":"455","DOI":"10.7326\/0003-4819-104-4-455","article-title":"Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women","volume":"104","author":"Taylor","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1023\/A:1008364222793_bb0095","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/0277-5379(91)90259-G","article-title":"\u2018Classical CMF\u2019 versus a three-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer","volume":"27","author":"Engelsman","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1023\/A:1008364222793_bb0100","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1984.2.12.1404","article-title":"Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer\u2019 The elimination of age trends in toxicity by using doses based on creatinine clearance","volume":"2","author":"Gelman","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008364222793_bb0105","first-page":"90","article-title":"A randomized phase II trial of mitoxantrone, 5-FU and high-dose leucovorin (NFL) versus cyclophosphamide, methotrexate, 5-FU (CMF) in the first-line treatment of metastatic breast cancer","volume":"14","author":"Hainsworth","year":"1995","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008364222793_bb0110","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF01806636","article-title":"Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer patients","volume":"37","author":"Mammoliti","year":"1996","journal-title":"Breast Cancer Res Treat"},{"key":"10.1023\/A:1008364222793_bb0115","first-page":"882","volume":"156","author":"Ibrahim","year":"1996","journal-title":"Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer Arch Intern Med"},{"key":"10.1023\/A:1008364222793_bb0120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.1992.03490010059030","article-title":"Chemotherapy of metastatic breast cancer in the elderly: The Piedmont Oncology Association experience","volume":"268","author":"Christman","year":"1992","journal-title":"JAMA"},{"key":"10.1023\/A:1008364222793_bb0125","first-page":"707","article-title":"Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine)","volume":"22","author":"Rittenberg","year":"1995","journal-title":"Oncol Nurs Forum"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419571526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419571526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/10\/4\/397\/19477331\/10-4-397.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T18:29:37Z","timestamp":1582223377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419571526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,4]]}},"alternative-id":["S0923753419571526"],"URL":"https:\/\/doi.org\/10.1023\/a:1008364222793","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1999,4]]}}}